Following radiotherapy, tumor-derived MPs from breast carcinoma cells carry elevated levels of immune-modulating proteins, including PD-L1, and are delivered to cytotoxic T lymphocytes (CTLs) (95). This evidence concerns the gene CD274 and neoplasm.